IP Library Granted Patent US 10,261,077
Granted Patent B2
US 10,261,077 · App. 15/155,594 · Granted Apr 16, 2019

Microfluidics based assay device

Inventors: Phillip Lowe (Tullibody, GB); Steven Alexander Keatch (Stirling, GB); Brian McGuigan (Stirling, GB)
Assignee: LUMIRADX UK LTD
G01N33/5438B01L3/502715B01L3/502761C12Q1/001C12Q1/006C12Y101/03004G01N27/3277G01N33/54326G01N33/54366B01L2200/04B01L2200/0647B01L2200/16B01L2300/0645B01L2300/0864B01L2300/161B01L2400/043B01L2400/0688G01N2333/904
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,261,077
App. No.
15/155,594
Granted
Apr 16, 2019
Kind
B2
Abstract

A subtractive corrective assay device and methodology, whereby ail required binding and label detection reagents are initially located within the detection zone. Application of a magnetic field is used to selectively remove bound label from the detection zone by means of paramagnetic particles. The relationship between measured label concentration before and after the application of a magnetic field within the detection zone is used to accurately measure analyte concentration within the sample.

Claims (17)

1. A method of determining the concentration of an analyte in a liquid sample, the method comprising:

(a) combining the sample with (i) an analyte binding agent that binds the analyte and (ii) a label for use in detecting the analyte, so that the analyte binding agent, the analyte, if present in the sample, and the label form an analyte binding agent/analyte/label complex;

(b) detecting a total level of the label present in a detection area, wherein the label is present in the analyte binding agent/analyte/label complex or is uncomplexed, to provide a first reference value;

(c) removing any binding agent/analyte/label complex from the detection area;

(d) detecting a level of any uncomplexed label and unreacted label that remains in the detection area after removal of the analyte binding agent/analyte/label complexes; and

(e) determining the concentation of the analyte present in the sample, if any, by subtracting the level of uncomplexed/unreacted label from the first reference value.

2. The method according to claim 1 , wherein the detection is performed directly on the sample, without any separation, washing step, or dilution of the sample.

3. The method according to claim 1 , wherein the detection is carried out electrochemically.

4. The method according to claim 3 , wherein an oxidising or reduction potential is used to measure a level of label.

5. The method according to claim 4 , wherein a potential is applied to reduce background effects caused by an electrochemical interferent that may be present in the sample.

6. The method according to claim 3 , wherein the label is glucose oxidase.

7. The method according to claim 6 , further comprising a peroxidase and a mediator that can be converted between oxidised and reduced forms that can be electrochemically detected.

8. The method of claim 7 , wherein the peroxidase is horseradish peroxidase.

9. The method of claim 7 , wherein the mediator is ferrocyanide or ABTS.

10. The method according to claim 1 , wherein the binding agent is coupled to a particle capable of forming a complex with analyte present in the sample that can be removed, when complexed or uncomplexed with analyte from the detection area.

11. The method according to claim 10 , wherein the particle is a paramagnetic particle that can be removed by a magnet or electromagnet.

12. The method according to claim 1 , wherein the sample is a sample of whole blood.

Assignments (10)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY, RECORDED ON MARCH 30, 2021 AT REEL/FRAME 055850/0771 Recorded Aug 5, 2024
From: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
To: LUMIRADX INTERNATIONAL LTD; LUMIRADX UK LTD
Reel/Frame 068327/0149 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Mar 30, 2021
From: LUMIRADX INTERNATIONAL LTD; LUMIRADX UK LTD
To: BIOPHARMA CREDIT PLC
Reel/Frame 055850/0771 →
RELEASE OF SECURITY INTEREST Recorded Mar 23, 2021
From: WILMINGTON TRUST (LONDON) LIMITED
To: LUMIRADX INTERNATIONAL LIMITED
Reel/Frame 055680/0327 →
RELEASE OF SECURITY INTEREST Recorded Mar 18, 2021
From: KENNEDY LEWIS INVESTMENT MANAGEMENT LLC
To: LUMIRADX UK LIMITED; LUMIRADX INTERNATIONAL LIMITED
Reel/Frame 055636/0739 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Sep 20, 2019
From: LUMIRADX UK LTD
To: KENNEDY LEWIS INVESTMENT MANAGEMENT LLC, AS AGENT
Reel/Frame 050452/0742 →
NOTICE OF SUCCESSION OF AGENCY Recorded Feb 23, 2017
From: UBS FOCUS FUND LUMIRADX 1-B, LLC
To: WILMINGTON TRUST (LONDON) LIMITED
Reel/Frame 041793/0126 →
SECURITY INTEREST Recorded Oct 19, 2016
From: LUMIRADX UK LIMITED
To: USB FOCUS FUND LUMIRADX 1-B, LLC
Reel/Frame 040420/0123 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2016
From: LOWE, PHILIP; KEATCH, STEVEN ALEXANDER; MCGUIGAN, BRIAN
To: MULTI-SENSE TECHNOLOGIES LIMITED
Reel/Frame 040014/0960 →
CHANGE OF NAME Recorded Sep 12, 2016
From: MULTI-SENSE TECHNOLOGIES LIMITED
To: LUMIRADX TECHNOLOGY LTD.
Reel/Frame 039703/0254 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2016
From: LUMIRADX TECHNOLOGY LTD.
To: LUMIRADX UK LTD.
Reel/Frame 039703/0259 →
Priority Claims (1)
GB 1102037.7 · Feb 7, 2011 · national
Continuity (2)
Continuation 13983650
Related Publication 20160320374A1 · Nov 3, 2016